uniQure N.V. Increase (Decrease) in Contract with Customer, Asset
uniQure N.V. (QURE) reported Increase (Decrease) in Contract with Customer, Asset of -$100.00 million for the 12-month period ending 2023-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2026-03-02
- uniQure N.V. increase (decrease) in contract with customer, asset for fiscal 2023 was -$100.00M, a 322.22% decline from fiscal 2022.
- uniQure N.V. increase (decrease) in contract with customer, asset for fiscal 2022 was $45.00M, a 18.18% decline from fiscal 2021.
- uniQure N.V. increase (decrease) in contract with customer, asset for fiscal 2021 was $55.00M.
| Period end | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|
| 2023-12-31 | -$100.00M 10-K · filed 2026-03-02 |
| 2022-12-31 | $45.00M 10-K · filed 2025-02-27 |
| 2021-12-31 | $55.00M 10-K · filed 2024-02-28 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |